Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Relapsed/Refractory AML or ALAL
NCT06177067Phase 1Recruiting
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Apr 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML) and acute leukemia of ambiguous lineage (ALAL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Safety and tolerability at 43 days. Started Apr 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)acute leukemia of ambiguous lineage (ALAL)
Beyond the preview
Go deeper on NCT06177067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06177067.